A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Aldesleukin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 25 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 02 Mar 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 31 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.